1. Home
  2. Drugs
  3. Drug Safety and Availability
  4. Postmarket Drug Safety Information for Patients and Providers
  5. Opioid Overdose Reversal Medications
  1. Postmarket Drug Safety Information for Patients and Providers

Opioid Overdose Reversal Medications

Opioid overdose persists as a major public health issue in the U.S., primarily driven by synthetic opioids like illicit fentanyl. The FDA continues to take actionable steps that support the availability and accessibility of opioid overdose reversal medications, such as naloxone and nalmefene, as well as the development of novel overdose reversal products. These life-saving medications are an important tool to reverse opioid overdose and can be administered by individuals without medical training, as shown on CDC’s website. They have no abuse potential, and some are available without a prescription.

Broadening Access to Opioid Overdose Reversal Medications

The FDA understands the importance of having opioid overdose reversal medications available and accessible for community use. To support these efforts, the FDA has approved naloxone nasal spray for purchase without prescription (over the counter, [OTC]), extended the shelf life of multiple naloxone products, approved multiple generic naloxone products, and hosted public workshops and stakeholder calls. Key activities include:

Advancing Evidence-Based Treatment for Opioid Overdose

The FDA approved two medications as safe and effective treatments for known or suspected opioid overdose: naloxone and nalmefene. FDA-approved medications can be found at Drugs@FDA. The FDA is working to identify additional treatment needs and support the development of new, evidence-based treatment options for opioid overdose. Key activities include:

FDA Resources

 

Back to Top